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Angiogenesis is regulated, under both physiological and pathological conditions, by numerous “non-classic”
pro-angiogenic factors, including fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), and
placental growth factor (PlGF), and “non-classic” pro-angiogenic factors, including granulocyte colony stimulating
factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), and erythropoietin (EPO). In the context
of the most important discoveries in this field, this review article summarizes the important role played by the
Italian scientists in the course of the last twenty years.
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In 1945, Algire and Chalkley were the first to appreciate
that growing malignant tumors could continuously elict
new capillary growth from the host [1]. In 1970s, it was
widely accepted that tumors did not produce specific
angiogenic proteins. In 1971, Judah Folkman isolated the
first angiogenic factor, and called it “Tumor Angiogenesis
Factor” (TAF). He fractioned by gel-filtration on Sephadex
G100 the homogenate of a Walker 256 carcinoma and
obtained a fraction with a strong angiogenic activity with a
molecular weight of about 10,000 Dalton, consisting of
25% RNA, 10% proteins, 58% carbohydrates, and a lipid
residue. Several other low molecular weight angiogenic
factors were isolated from the Walker 256 carcinoma,
capable to induce an angiogenic response in vivo when
tested on rabbit cornea or chick embryo chorioallantoic
membrane (CAM), and in vitro on cultured endothelial
cells [2]. Subsequently, TAF was extracted from several
tumor cell lines.
Starting from the discovery of TAF, other pro-angiogenic
molecules have been isolated, namely basic fibroblast
growth factor (bFGF)/fibroblast growth factor-2 (FGF-
2), vascular endothelial growth factor (VEGF)/vascular
permeability factor (VPF), and placental growth factor
(PlGF). In the meantime, it has been demonstrated theCorrespondence: domenico.ribatti@uniba.it
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including hematopoietic cytokines, namely granulocyte
colony stimulating factor (G-CSF), granulocyte macrophage
colony stimulating factor (GM-CSF), and erythropoi-
etin (EPO).
In this context, Folkman hypothesized that tumor growth
is angiogenic-dependent and that inhibition of angio-
genesis could be therapeutic, introducing the term anti-
angiogenesis. Investigations on neoplastic transformation
have focused on transformed cells and in the meantime
have addressed the tumor microenvironment and docu-
mented its importance in tumor progression. The patho-
genesis of most cancers, in fact, includes complex and
mutual interactions affecting tumor cells, inflammatory
cells and various components of the extracellular matrix.
These concepts are now widely accepted and supported
by experimental and clinical studies.
Anti-angiogenic agents may be divided in two major
groups: indirect agents that block the expression or the
activity of angiogenic molecules, or the expression of
their receptors on endothelial cells, and agents able to
directly affect endothelial cell function or survival.
Beginning in the 1980s, the industry began exploiting the
field of anti-angiogenesis for creating new therapeutic
molecules in angiogenesis-dependent diseases. Bevacizumab
(Avastin) was the first angiogenesis inhibitor approved by
the Food and Drug Adminstration for the treatment of
colorectal cancer in February 2004, administered in com-
bination with irinotecan, 5-fluorouracil and leucovirin; ithis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 A port trait of Marco Presta.
Figure 2 A port trait of Napoleone Ferrara.
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cytotoxic chemotherapy, in other cancers, demonstrating
an improvement in overall survival or delayed tumor
progression compared to chemotherapy alone.
Here, I have summarized the fundamental contribution
of Italian scientists to the discovery of the most important
angiogenic factors.
The contribution of Marco Presta to isolation of
bFGF/FGF-2
In 1970s, Armelin and Gospodarowicz demonstrated
that the bovine pituitary contains a potent mitogen for
fibroblasts, endothelial cells and chondrocytes, with a
molecular weight of 14,000-16,000 Daltons and a basic
isoelectric point. This factor was named fibroblast growth
factor [3-6].
In 1980s, Shing at the Children’s Hospital in Boston
discovered a tumor-derived factor very similar to the
agent discovered by Gospodarowicz, able to bound with
such a high affinity to heparin, with a molecular weight
of 14,800, which stimulated the proliferation of capillary
endothelial cells in vitro, and angiogenesis in vivo in
the chick CAM assay [7,8]. Amino acid sequence was
determined by Esch et al. [9] and it was purified from
bovine pituitary and brain [10].
In 1986, Marco Presta (Figure 1), Moscatelli, and Rifkin,
working at the New York University, isolated an angio-
genic factor from human placenta and human hepatoma
cells, able to stimulate DNA synthesis, motility, and prote-
ase production in capillary endothelial cells and induced
angiogenesis in vivo [11,12]. Amino acid sequence demon-
strated that this factor was human bFGF.
The contribution of Napoleone Ferrara to isolation of
VEGF/VPF
Napoleone Ferrara (Figure 2) joined Genentech in 1988
after postdoctoral training at the University of California
at San Francisco, in the Department of Obstetrics, Gyne-
cology, and Reproductive Sciences in Richard Wiener’s
laboratory, where he isolated and cultured follicular
cells, a population of non–hormone-secreting cells from
the anterior pituitary of cows [13]. Ferrara demonstrated
that supernatants from cultures of follicular cells stimu-
lated endothelial cells proliferation, and supposed that
they secreted an angiogenic protein.
In 1989, Ferrara and Henzel isolated a diffusible endo-
thelial cell-specific mitogen from medium conditioned
by bovine pituitary follicular cells, which they named
VEGF, distinct from bFGF and indeed did not match any
known protein in available databases [14].
In 1979, Harold D. Dvorak, working at the Harvard
Medical School in Boston, tested cell-free supernatants
from several human and animal tumor cell lines in the
permeability Miles assay [15], and found that theygenerated an intense blue spot due to extravasated Evans
blue, and called this activity VPF [16]. VPF showed a
potency some 50,000 times that of histamine [17,18].
The molecular cloning of VEGF and VPF revealed that
both activities are embodied in the same molecule.
Figure 3 A port trait of Maria Graziella Persico.
Figure 4 A port trait of Federico Bussolino.
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Lewis Williams at the University of California at San
Francisco, VEGFR-1 was shown to be an high-affinity
VEGF receptor [19]. Moreover, Ferrara demonstrated that
VEGFR-1 expression was up-regulated by hypoxia via a
hypoxia-inducible factor (HIF)-1-dependent mechanism
[20] and that VEGFR-1 binds not only VEGF-A, but also
PlGF [21]. In 1996, Ferrara [22] and Carmeliet et al. [23]
demonstrated an important role of VEGF in embryonic
vasculogenesis and angiogenesis.
In 1993, Ferrara demonstrated that anti-VEGF mono-
clonal antibodies exerted an inhibitory effect, ranging
between 70% and more than 95%, on the growth of tumor
cell lines injected subcutaneously in nude mice [24].
These findings provided the first direct demonstration
that inhibition of the action of an endogenous angio-
genic factor may result in suppression of tumor growth
in vivo. The first anti-angiogenic agent approved by
the Food and Drug Administration was bevacizumab
(Avastin; Genentech), a humanized version [25] of an
anti-VEGF monoclonal antibody discovered by Ferrara
[24]. Bevacizumab bound and neutralized all human
VEGF-A isoforms and bioactive proteolytic fragments,
inhibited the growth of human tumor cell lines in nude
mice [25].
More recently, Ferrara has demonstrated that related
endocrine gland-VEGF (EG-VEGF) and Bv8 proteins,
also known as prokineticin 1 (Prok1) and prokineticin 2
(Prok2), induce both angiogenesis and haematopoietic
cell mobilization [26].
The contribution of Graziella Persico to isolation of PlGF
Maria Graziella Persico (Figure 3), working at the Institute
of Genetics and Biophysics in Naples, cloned and purified
PlGF and determined its structure [27,28]. PlGF exhibited
remarkable structural similarities to VEGF-A, although
PlGF and VEGF-A showed only a 42% amino acid se-
quence identity, as well as significant functional differ-
ences. Persico demonstrated also that the human PlGF
gene is located on chromosome 14 and consists of seven
exons [29].
PlGF was originally identified in the placenta, where it
has been proposed to control trophoblast growth and
differentiation [29,30], playing a role during invasion of
the trophoblast into the maternal decidua [31]. Ziche et al.
[32] demonstrated that PlGF-1 was angiogenic in vivo in
the rabbit cornea and in the chick CAM. PlGF and VEGF
were able to induce the formation of new capillaries
approximately 36 h earlier than FGF-2, suggesting a
faster recruitment of endothelial cells.
In 2001, Persico in collaboration with Carmeliet, showed
that loss of PlGF does not affect development, reproduc-
tion or postnatal life [33]. However, in ischemic conditions
such as myocardial infarction or following ligation ofthe hind limb artery, PlGF−/− mice showed reduced
angiogenesis and arteriogenesis [33]. Administration of
recombinant human PlGF was able to reverse the revascu-
larization defect within the infarcted area. VEGF-A and
VEGFR-2 expression remains at comparable levels in
PlGF−/− mice, in which the loss of PlGF blocks the re-
cruitment of macrophages, suggesting that PlGF has a
specific role in macrophage mobilization [33].
As concerns the effect of an anti-PlGF antibody, even
if evidence has shown that it exerts an anti-angiogenic
action, Bais et al. [34] demonstrated that although anti-
Figure 5 A port trait of Domenico Ribatti.
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of tumor cells cells, and growth of a tumor overexpress-
ing the PlGF receptor (VEGFR-1), neutralization of PlGF
using blocking antibodies had no significant effect on
tumor angiogenesis in different animal models.Figure 6 Cross-talk between the biological activities of the principal aAngiogenic activity of classical hematopoietic cytokines
G-CSF and GM-CSF can promote proliferation and differ-
entiation of myeloid-committed progenitors, including
eosinophils, basophils, megakaryocytes, and erythroid and
dendritic cells in synergy with other factors.
Federico Bussolino (Figure 4), working at the University
of Turin, demonstrated for the first time the presence of
specific receptors for G-CSF and GM-CSF on the surface
of endothelial cells [35-38]. Soldi et al. [39] demonstrated
that endothelial cells express the α and ß subunits of
GM-CSF-receptor and that GM-CSF is able to activate
JAK2 [40]. Moreover, Bussolino showed that GM-CSF
induces endothelial cells to migrate, proliferate and release
plasminogen activator and is angiogenis in vivo in the
rabbit cornea and in the chick CAM assay [35-38,40,41].
Bussolino has also demonstrated for the first time the an-
giogenic activity of hepatocyte growth factor/scatter
factor (HGF/SF), originally identified by Nakamura in
1984 [42].
It is to mention the contribution of another scientist
working in Turin, Luca Tamagnone, to the demonstra-
tion of the angiogenic activity of semaphorins and plexin
[43] and that another Italian scientist, Giovanna Tosato,
working in Bethesda, has demonstrated that semaphorin
6A mediated endothelial cell survival by modulating VEGF
signaling [44].
Erythropoiesis has been considered the sole physiological
action of EPO until EPO and EPO receptor (EPOR) have
been found to be expressed in other sites besides kidney,
including bone marrow macrophages, neurons, astrocytes,
microglia and even oligodendrocytes, cervix, endometrium,
ovary, oviduct, and throphoblast cell of the human
placenta.
Moreover, EPO induces endothelial cell proliferation and
migration [45,46] and stimulates angiogenesis on rat aortic
rings in vitro [47]. In 1999, Domenico Ribatti (Figure 5),ngiogenic factors.
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first time that recombinant human EPO (rhEPO) induces
a pro-angiogenic phenotype in human endothelial cells
[48], including increase in cell proliferation and matrix
metalloproteinase-2 production and differentiation into
vascular tubes. Accordingly, endothelial cells expressed
EPOR that bound to JAK2 and induced its transient acti-
vation after rhEPO exposure. In the CAM assay, the an-
giogenic activity of the rhEPO was similar to that exerted
by FGF-2 in the absence of a significant mononuclear cell
infiltrate, and endothelial cells of the CAM expressed
EPOR. Overall, these data demonstrated that EPO acts as
a direct angiogenic factor.
Concluding remarks
Angiogenesis is controlled by the balance between mole-
cules that have positive and negative regulatory activities
and this concept has led to the notion of the angiogenic
switch, which depends on an increased production of one
or more positive regulators of angiogenesis [49]. Most
human tumors arise and remain in situ without angiogen-
esis for a long time before switching to an angiogenic
phenotype, though a pre-neoplastic stage as occurs in
breast and cervical carcinomas, which becomes neovas-
cularized before the malignant tumor appears.
Activation of the angiogenic switch has been attributed
to the synthesis or release of angiogenic factors, and
accordingly to the balance hypothesis, the level of angio-
genesis inducers and inhibitors regulates angiogenesis in
physiological conditions. This balance is altered in patho-
logical conditions, including chronic inflammations and
tumors, as a consequence of an increase bioavailability or
activity of the inducer proteins, or reducing the concentra-
tions of endogenous angiogenesis inhibitors.
Angiogenesis is regulated, under both physiological and
pathological conditions, by numerous “classic” pro-angio-
genic factors, including FGF-2, VEGF, and PlGF (Figure 6).
Moreover, evidence has been accumulated that in addition
to the “classic” factors, many other “non-classic factors”,
including G-CSF, GM-CSF and EPO, play an important
role in angiogenesis (Figure 6) [50]. In this article, I have
emphasized the important role played by the Italian scien-
tists in the course of the last twenty years to the discovery
and characterization of these “classic” and “non-classic”
factors.
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